Uno M, Wirschubsky Z, Babonits M, Wiener F, Sümegi J, Klein G
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
Int J Cancer. 1987 Oct 15;40(4):540-9. doi: 10.1002/ijc.2910400418.
Somatic cell hybrids were generated between an MCF-virus-induced 15-trisomic T-cell lymphoma of AKR origin with a proviral insertion near the c-myc locus, and normal diploid fibroblasts or lymphocytes of CBAT6T6 origin. Three lymphoma/fibroblast fusions were performed. Six independently-derived clones from 2 fusions were tested for tumorigenicity. Three of the 6 clones were weakly malignant (take incidence 20% below), and 3 were strongly malignant (take incidence over 80%). All 3 lymphoma/lymphocyte hybrids and 6 derived clones were strongly malignant. All hybrids contained a nearly complete chromosomal complement of both parental cells. This was confirmed at the molecular level by determining the ratio of germ-line (G) vs. rearranged (R) myc-carrying Eco RI fragments that showed the expected 1.9-2.7:1 proportion. Malignant segregants selected from the weakly malignant lymphoma/fibroblast hybrids by in vivo inoculation showed changed 15-chromosome ratios. Four out of the 6 clones showed amplification of the lymphoma-derived 15-chromosome that carries the R-myc fragment and a concomitant decrease in the average number of the G-myc-carrying chromosomes. This was deduced from the fact that the G:R ratio was between 2 and 3:1 in the in vitro hybrids but became inverted (1:2-3) in the tumors. Two tumors showed no amplification of R-myc. G-myc was decreased. One of these tumors showed a change in the G:R ratio from 2.5:1.0 to 1.2:1.0, while the other was essentially unchanged (1.9:1.0 in the in vitro clone and 2.2:1.0 in the derived tumor). These findings support the notion that both the amplification of the lymphoma-derived 15-chromosome with the retrovirally rearranged c-myc carrying fragment and/or the loss of the G-myc-carrying 15-chr can contribute to the tumorigenic potential of the hybrids.
在源自AKR的MCF病毒诱导的15 - 三体T细胞淋巴瘤(其原病毒插入靠近c - myc基因座)与源自CBAT6T6的正常二倍体成纤维细胞或淋巴细胞之间产生了体细胞杂种。进行了三次淋巴瘤/成纤维细胞融合。对来自2次融合的6个独立衍生克隆进行了致瘤性测试。6个克隆中有3个为弱恶性(接种发生率低于20%),3个为强恶性(接种发生率超过80%)。所有3个淋巴瘤/淋巴细胞杂种及其6个衍生克隆均为强恶性。所有杂种均包含两个亲代细胞几乎完整的染色体组。通过测定携带种系(G)与重排(R)的myc的Eco RI片段的比例,在分子水平上证实了这一点,该比例显示出预期的1.9 - 2.7:1。通过体内接种从弱恶性淋巴瘤/成纤维细胞杂种中选择的恶性分离株显示15号染色体比例发生了变化。6个克隆中有4个显示携带R - myc片段的淋巴瘤来源的15号染色体发生扩增,同时携带G - myc的染色体平均数量减少。这是从以下事实推断出来的:在体外杂种中G:R比例在2到3:1之间,但在肿瘤中变为倒置(1:2 - 3)。两个肿瘤未显示R - myc扩增。G - myc减少。其中一个肿瘤的G:R比例从2.5:1.0变为1.2:1.0,而另一个基本未变(体外克隆中为1.9:1.0,衍生肿瘤中为2.2:1.0)。这些发现支持了这样一种观点,即携带逆转录病毒重排的c - myc片段的淋巴瘤来源的15号染色体的扩增和/或携带G - myc的15号染色体的丢失都可能有助于杂种的致瘤潜力。